CEO Hemostemix emphasizes the increasing volatility of $HEM.


Thomas Smeenk on the latest update stated “for the stem cell space it is the right time to take a bite of the apple” Thomas later said the management board have invested about $4.5 Million in the stock because of the firm belief.


Comments

Leave a Reply

Your email address will not be published. Required fields are marked *